Parse Biosciences – a leading provider of accessible and scalable single-cell sequencing solutions – recently announced it had closed a total of $50 million in financing from a Series C equity raise and the closing of a debt facility. And Soleus Capital led the Series C equity financing – which included participation by new and current investors, including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital. Horizon Technology Finance Corporation provided the debt facility.
Bringing the total funding to over $100 million, this financing will enable Parse to fuel its expansion, further scale to meet the increasing demand for its technology, and continue to serve its academic, biotech, and pharma customers. Enabling researchers to perform single-cell sequencing with unprecedented scale and ease without the need for custom instrumentation, Parse’s single-cell portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and data analysis solutions.
The approach and inherent scalability of Parse’s technology have led to critical discoveries across a wide range of research areas, addressing researchers’ questions more comprehensively than other single-cell products. And in a relatively short time span, Parse broadened its foundational Evercode technology to empower researchers to expand to new applications such as immune profiling and pooled CRISPR screens.
Since first launching in 2021, Parse’s products have been widely adopted across the world’s leading pharmaceutical companies and research universities and institutions. And the company’s products are now available in a growing number of key international markets, including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea.
KEY QUOTES:
“Customer response to our products has been extraordinary, with researchers around the world leveraging our technology to make significant scientific advances. The resounding support from investors will further our mission to make scalable single-cell projects routine. We’re especially excited to continue supporting many of the large-scale programs happening within biopharma.”
— Parse CEO and co-founder Alex Rosenberg, Ph.D
“Parse’s unique technology is enabling investigators to conduct groundbreaking research and expand the overall genomics market. We are proud to partner with Parse and its management team as the company grows into a preeminent player in the genomics space.”
— Soleus Capital partner David Canner
“Parse’s transformative technology is paving the way for single cell sequencing to significantly innovate and enhance human health research and treatments. We are excited to support Parse as it develops new genomic solutions and further expands its operations.”
— Gerald A. Michaud, President of Horizon
